Watson gets guaranteed product to sell in Lidoderm deal with Endo
This article was originally published in Scrip
Executive Summary
Watson Pharmaceuticals has secured certainty of early launch and a supply of branded product to sell as part of an unusual agreement signed with Endo Pharmaceuticals and its partner Teikoku Seiyaku to settle patent litigation over pain product Lidoderm.